Profile - Biotech / Targeted Protein Degradation
Lycia Therapeutics
A 36-person biotech that figured out how to drag the body's worst-behaved proteins into the cellular incinerator - and got Eli Lilly to write the first check.
A 36-person biotech that figured out how to drag the body's worst-behaved proteins into the cellular incinerator - and got Eli Lilly to write the first check.
Lycia Therapeutics builds LYTACs - lysosomal targeting chimeras - bifunctional molecules with one hand on a disease-driving protein and the other on a receptor that shuttles cargo into the cell. The receptor does what it always does. The cell drags the molecule inward. The protein, now an unwilling passenger, ends up in the lysosome, the cell's acidic recycling bin. Inside, it is dismantled. The bouncer never had to make a decision.
A LYTAC is a chemical handshake. One end grabs a target protein floating in the bloodstream or stuck on a cell surface. The other end grabs a receptor whose job is to ferry cargo into the cell. Together, they ride the cell's own delivery system into the lysosome - where pH drops, enzymes wake up, and the target gets digested. It is targeted protein degradation, but outside the cell, where most drugs cannot reach.
Roughly 40% of proteins implicated in disease live outside the cell - circulating in blood, sitting on membranes, doing their damage in places small-molecule degraders like PROTACs simply cannot follow. That is the territory Lycia claims.
The science came first. Carolyn Bertozzi - the Stanford chemist, HHMI investigator, and 2022 Nobel laureate - had spent decades teaching molecules to find each other inside living systems. In 2019, Versant Ventures opened up its Inception Sciences incubator in San Francisco, paired Bertozzi's lysosome-targeting work with seasoned drug hunters, and Lycia was born. The name itself winks at the lysosome - the organelle at the center of the platform.
In April 2020 the company hired Aetna Wun Trombley, the former President and COO of NGM Biopharmaceuticals, to run it. A year later, Eli Lilly walked in not just as a partner but as an investor. The Series B in 2021 brought in Redmile, RTW, Cowen, Invus, and Alexandria. By May 2024, Venrock was leading an oversubscribed $106.6M Series C - the kind of round that buys runway through the first humans.
What makes Lycia unusual is not the chemistry alone. It is the discipline. Thirty-six people. One platform. A pipeline that refuses to chase every adjacent indication just because the platform might work there. The current focus is autoimmune and inflammatory disease - territories where pathogenic autoantibodies and immune complexes float through the bloodstream begging to be cleared.
Most biotech press releases promise a "broad platform." Lycia has one too. They simply talk about it less.
The Series C cap table reads like a list of who's-still-allowed-to-write-checks-in-biotech: Venrock Healthcare Capital Partners (lead), Janus Henderson, Marshall Wace, Franklin Templeton, Redmile, RTW, Blue Owl Healthcare Opportunities, Invus, Eli Lilly, Alexandria Venture Investments. Crossovers and strategics in one room, which usually means the company is preparing to walk through the IND door.
The discovery engine: a modular framework for pairing target binders with internalizing-receptor binders to produce degradation candidates.
Lead focus: depleting circulating autoantibodies, pathogenic immune complexes, and disease-driving membrane proteins.
Strategic discovery deal signed in August 2021 to co-develop LYTAC degraders against Lilly-selected targets. Lilly is also an equity investor.
Incubated in Versant's Inception Sciences Discovery Engine; scientific founder Carolyn Bertozzi's Stanford lab seeded the platform.
If you live with an autoimmune disease, the working theory of most existing therapies is suppression: dial down the immune system, hope the side effects stay manageable. Extracellular protein degradation flips the question. Instead of muting the orchestra, you remove a single bad instrument. The autoantibody driving the disease, the immune complex inflaming the tissue, the surface protein telling cells to misbehave - gone. Cleanly. Catalytically.
For drug developers, the same platform offers a tool: a way to drug targets historically labeled "undruggable" because they sit outside the cell. For investors, it is a wedge into a market - targeted protein degradation - that intracellular PROTAC players cannot reach.